

Supplementary Material IV: List of articles eliminated from the final screening stage (Full-text review)

Item	Title of Article	The reason for exclusion
1	Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study	Study design
2	Comparative Effectiveness of Linezolid and Vancomycin among a National Cohort of Patients Infected with Methicillin-Resistant Staphylococcus aureus	Study design
3	Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China	Study design
4	Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital	Interpretation or editorial letters
5	Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes	Difference in the type of infection or the antibiotic under investigation
6	Management of methicillin-resistant Staphylococcus aureus pneumonia	Difference in the type of infection or the antibiotic under investigation
7	Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers	Difference in the type of infection or the antibiotic under investigation
8	Choosing between methods to prevent methicillin-resistant staphylococcus aureus in Intensive Care Units	Focus on prevention and diagnosis rather than treatment
9	Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid	Studies without health economics models
10	Cost of nosocomial pneumonia: the example of vancomycin versus linezolid-shorter stay or fewer complications?	Studies that did not constitute a complete economic evaluation
11	Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective	Studies without health economics models
12	Direct medical costs associated with using vancomycin in methicillin-resistant staphylococcus aureus infections: an economic model	Studies that did not constitute a complete economic evaluation
13	Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy	Study design
14	Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial	Difference in the type of infection or the antibiotic under investigation
15	Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia	Focus on prevention and diagnosis rather than treatment
16	Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study	Studies without health economics models
17	Comparison of Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Pneumonia: Institutional Implications	Studies that did not constitute a complete economic evaluation
18	Antibiotic treatment against methicillin-resistant staphylococcus aureus hospital-and ventilator-acquired Pneumonia: A step forward but the battle continues	Interpretation or editorial letters
19	Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections?	Study design
20	Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective	Difference in the type of infection or the antibiotic under investigation
21	Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin resistant staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study	Studies that did not constitute a complete economic evaluation
22	Management and treatment considerations for infections caused by methicillin-resistant Staphylococcus aureus	Study design
23	Cost-effectiveness analysis of treatment of methicillin-resistant staphylococcus aureus bacteremia and endocarditis is a difficult issue	Difference in the type of infection or the antibiotic under investigation
24	Efficacy of linezolid versus comparator therapies in Gram-positive infections	Studies that did not constitute a complete economic evaluation
25	Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin	Difference in the type of infection or the antibiotic under investigation